1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Gotistobart: new trials by email Literature Review of Gotistobart trials Research Report on Gotistobart
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 148 | 2023-12-11 | 2026-05-22 |
OncoC4, Inc. (1)
United States (1)
David Wise, MD (1) · Mark Stein, MD (1)